EDAP TMS
United States · Biotechnology, Health Care, Manufacturing
EDAP TMS is a high-tech medical company listed on the Nasdaq (EDAP) which develops, manufactures and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU d
Key facts
- Headquarters
- United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (FOCL)
- Website
- edap-tms.com
- Company page
Recent activity at EDAP TMS
- : SEC 8-K (8.01): On August 11, 2026, EDAP TMS S.A. entered into an underwriting agreement for a public offering of 8,425,000 American Depositary Shares (ADSs) at $4.75 per ADS. The offering closed on August 14, 2026. As part of the agreement, the company granted the underwriters a 30-day option to purchase an additional 1,263,750 ADSs, which the underwriters fully exercised on the same day. The additional issuance is expected to close on August 19, 2026, and will generate approximately $5.6 million in net proceeds for the company after costs. This filing discloses significant updates related to the securities offering and financial implications for EDAP TMS S.A.
- : SEC 8-K (1.01): On August 11, 2026, EDAP TMS S.A. entered into an Underwriting Agreement with TD Securities (USA) LLC and Mizuho Securities USA LLC for an underwritten public offering of 8,425,000 American Depositary Shares (ADSs) at a price of $4.75 per ADS, set to close on August 14, 2026. The offering is expected to yield approximately $37.1 million in net proceeds, which the company plans to use for operating costs, capital expenditures, and general corporate purposes. The Underwriting Agreement grants the underwriters a 30-day option to purchase an additional 1,263,750 ADSs and includes customary terms such as indemnification and lock-up agreements for the company’s executive officers and directors, restricting certain sales for 90 days. This transaction reflects the company's strategic move to enhance its capital resources.
- : SEC 8-K (8.01): On August 11, 2026, the Company released an Investor Presentation that outlines its expansion plans for the Focal One Robotic HIFU platform into new treatment indications, specifically for benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis. This presentation highlights significant market potential, with estimates of over 100 million men suffering from BPH and 38 million women affected by endometriosis globally, indicating a substantial addressable market. The Company's BPH program has received Institutional Review Board approval for its feasibility study in the U.S., while the endometriosis program is progressing through clinical development and has initiated a limited commercial launch in Europe. The filing underscores the investigational nature of these treatments, emphasizing that regulatory approvals are still pending and that the market responses may impact future developments positively or negatively.
- : SEC 8-K (1.01): On August 11, 2026, EDAP TMS S.A. entered into an underwriting agreement with TD Securities (USA) LLC and Mizuho Securities USA LLC for a public offering of 8,425,000 American Depositary Shares (ADSs), priced at $4.75 each. This agreement signifies a significant capital raising effort by the company, aiming to close the offering on August 14, 2026. The participation of established financial institutions as underwriters underscores the strategic importance of this transaction for the company’s growth and future initiatives.
- : EDAP TMS S.A. Completes Underwritten Public Offering of ADSs
- : SEC 8-K (7.01): On June 1, 2026, EDAP TMS S.A. presented information during the FocalTherics Investor Day, which was accessible to all participants via a live webcast. The event featured a presentation outlined in Exhibit 99.1, and included strategic updates relevant to investors. A replay of the presentation is available on the Company's Investor Relations website, indicating the Company's initiative to enhance investor engagement and transparency. This event reflects EDAP TMS S.A.'s ongoing commitment to provide timely information to its stakeholders.
- : SEC 8-K (8.01): On May 29, 2026, EDAP TMS S.A. announced its intention to operate under the new corporate name 'FocalTherics' with its American Depositary Shares (ADS) beginning to trade under the new ticker symbol 'FOCL' on June 1, 2026. Although the legal name will remain EDAP TMS S.A., shareholder approval for a future legal name change is planned. Additionally, the Company revealed plans to report its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments as discontinued operations in its upcoming financial statements, starting with Q2 2026 results. This strategic rebranding aims to enhance the Company’s market presence and align with its growth strategy. A related Investor Day event is scheduled for June 1, 2026, to discuss the new corporate identity and outlook.
- : SEC 8-K (7.01): On March 18, 2026, EDAP TMS S.A. provided a Regulation FD Disclosure regarding its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The company will present its latest insights and strategies at the conference, and the presentation materials are included as Exhibit 99.1. This presentation will be accessible via webcast on the Company's website, allowing investors to stay informed about the company's developments. The event's timing closely aligns with today's date, indicating a commitment to keeping stakeholders updated.
- : SEC 8-K (5.02): On February 10, 2026, Mr. Glen French resigned from the Board of Directors of EDAP TMS S.A. effective immediately, without any disputes with the company. Subsequently, on February 11, 2026, Mr. David Horn was appointed to fill this vacancy; he will serve on the audit and nominations committees. Mr. Horn, 58, has extensive experience in finance and strategic planning, having previously served as CFO of Seer, Inc. and in senior roles at Morgan Stanley. His appointment is subject to shareholder vote at the upcoming annual General Meeting.
- : SEC 8-K (5.02): On February 10, 2026, Mr. Glen French resigned from the Board of Directors of EDAP TMS S.A. and from its audit, compensation, and nominations committees, effective immediately. His resignation was not due to any disagreement with the Company or the Board. This change in management structure may impact strategic decision-making and overall governance of the organization, as the audit and compensation committees play critical roles in financial oversight and executive compensation policies. The notification of his resignation was made to the Board prior to the announcement.
EDAP TMS funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $40.0M |
Leadership
- François Dietsch, Global Chief Accounting Officer
- Ken Mobeck, Chief Financial Officer
Verified email and direct lines for EDAP TMS’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
EDAP TMS in the news
- FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026 - GlobeNewswire (Oct 22, 2026)
- EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share EDAP - FinancialContent (Oct 16, 2026)
- Two holders each report sole voting power over 3.49M shares in EDAP TMS (FOCL). - Stock Titan (Oct 19, 2026)
- Edap TMS SA (FOCL) (Q2 2026) Earnings Call Highlights: HIFU Revenue Surges 39% as Company ... - Yahoo Finance (Aug 13, 2026)
- EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share EDAP - FinancialContent (Oct 16, 2026)
- EDAP TMS S.A. (FOCL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow - Seeking Alpha (Sep 15, 2026)
- Technical Analysis of EDAP TMS S.A. (NASDAQ:FOCL) - TradingView (Jun 13, 2026)
- Edap Tms Unveils FocalTherics Pivot, Targets 40% Growth on HIFU Expansion - Yahoo Finance (Jun 01, 2026)
Companies similar to EDAP TMS
- Scarlet · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Healthium Medtech · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Capitan Orthopedics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Aspen Medical Products · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Total Joint Orthopedics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About EDAP TMS: questions and answers
What does EDAP TMS do?
EDAP TMS is a high-tech medical company listed on the Nasdaq (EDAP) which develops, manufactures and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU d
Where is EDAP TMS headquartered?
EDAP TMS is headquartered in United States.
Has EDAP TMS raised funding?
Yes. Fundz has recorded 1 funding event for EDAP TMS. The most recent, Post-IPO Equity of $40.0M, was in Aug 2026.
What is the latest news on EDAP TMS?
On Aug 19, 2026, SEC 8-K (8.01): On August 11, 2026, EDAP TMS S.A. entered into an underwriting agreement for a public offering of 8,425,000 American Depositary Shares (ADSs) at $4.75 per ADS. The offering closed on August 14, 2026. As part of the agreement, the company granted the underwriters a 30-day option to pu
Is EDAP TMS a public company?
Yes. EDAP TMS is publicly traded under the ticker FOCL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy